Baxter International Inc. (NYSE:BAX) saw unusually large options trading activity on Friday. Traders acquired 9,457 call options on the stock. This represents an increase of Infinity compared to the average volume of 0 call options.
Baxter International (NYSE:BAX) opened at $64.04 on Monday. Baxter International has a 12-month low of $43.13 and a 12-month high of $65.70. The company has a market cap of $34,891.03, a PE ratio of 26.46, a PEG ratio of 2.14 and a beta of 0.68. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.80 and a quick ratio of 2.22.
Baxter International (NYSE:BAX) last announced its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. Baxter International had a net margin of 9.88% and a return on equity of 15.00%. The company had revenue of $2.71 billion during the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter last year, the firm posted $0.56 EPS. The company’s quarterly revenue was up 5.8% on a year-over-year basis. sell-side analysts expect that Baxter International will post 2.43 earnings per share for the current year.
In other Baxter International news, Director Carole J. Shapazian sold 4,020 shares of the stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $61.61, for a total value of $247,672.20. Following the sale, the director now directly owns 13,868 shares in the company, valued at $854,407.48. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Third Point Llc sold 5,000,000 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $64.23, for a total transaction of $321,150,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,035,050 shares of company stock worth $323,308,587. Company insiders own 0.05% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of BAX. Baker Ellis Asset Management LLC acquired a new stake in shares of Baxter International during the 2nd quarter worth about $109,000. Acrospire Investment Management LLC lifted its stake in shares of Baxter International by 71.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,402 shares of the medical instruments supplier’s stock worth $145,000 after buying an additional 1,000 shares during the last quarter. Harvest Fund Management Co. Ltd lifted its stake in shares of Baxter International by 8.4% during the 2nd quarter. Harvest Fund Management Co. Ltd now owns 2,928 shares of the medical instruments supplier’s stock worth $177,000 after buying an additional 226 shares during the last quarter. Captrust Financial Advisors acquired a new stake in shares of Baxter International during the 2nd quarter worth about $188,000. Finally, Salem Investment Counselors Inc. lifted its stake in shares of Baxter International by 400.0% during the 1st quarter. Salem Investment Counselors Inc. now owns 3,800 shares of the medical instruments supplier’s stock worth $198,000 after buying an additional 3,040 shares during the last quarter. Institutional investors own 82.85% of the company’s stock.
A number of brokerages recently commented on BAX. BidaskClub upgraded shares of Baxter International from a “buy” rating to a “strong-buy” rating in a report on Monday, August 14th. Zacks Investment Research lowered shares of Baxter International from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Morgan Stanley raised their price objective on shares of Baxter International from $59.00 to $62.00 and gave the stock an “equal weight” rating in a report on Thursday, October 26th. Barclays PLC raised their price objective on shares of Baxter International from $64.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, July 27th. Finally, Cowen and Company restated a “neutral” rating on shares of Baxter International in a report on Friday, October 13th. Six research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $67.00.
COPYRIGHT VIOLATION WARNING: “Baxter International Target of Unusually Large Options Trading (BAX)” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://ledgergazette.com/2017/11/13/baxter-international-target-of-unusually-large-options-trading-bax.html.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.